Viracta Therapeutics Inc (VIRX) Debt by Year
Viracta Therapeutics Inc carried $0 in long-term debt against $12.3M in cash and equivalents at the end of fiscal year 2023. This represents a decrease of 100.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2009 to 2023, and the quarters Viracta Therapeutics Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
VIRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K | FY1010-K | FY0910-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0-100.0% | $24.9M+416.2% | $4.8M+16.0% | $4.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $12.3M-66.5% | $36.8M-64.5% | $103.6M+119.9% | $47.1M+158.5% | $18.2M+33.0% | $13.7M-49.2% | $27.0M+234.9% | $8.1M-70.0% | $26.9M+21.2% | $22.2M+46.7% | $15.1M+1.2% | $14.9M+60.5% | $9.3M-34.5% | $14.2M+234.0% | $4.3M |
VIRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-Q | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $16.9M | $18.7M-9.8% | $18.7M-18.2% | $0-100.0% | $0-100.0% | $20.8M+327.8% | $22.8M+371.7% | $24.9M+416.2% | $4.9M-3.1% | $4.9M+17.0% | $4.8M+4.5% | $4.8M+16.0% |
| Cash & Equivalents | $13.1M+2.1% | $14.0M-2.2% | $12.1M-33.4% | $12.3M-66.5% | $12.9M-45.2% | $14.3M-82.5% | $18.1M-80.4% | $36.8M-64.5% | $23.5M-78.9% | $81.6M-33.5% | $92.2M-28.6% | $103.6M+119.9% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Viracta Therapeutics Inc financials
Frequently Asked Questions
What was Viracta Therapeutics Inc's long-term debt in fiscal year 2023?
Viracta Therapeutics Inc carried $0 in long-term debt against $12.3M in cash and equivalents at the end of fiscal year 2023.
How fast is Viracta Therapeutics Inc's long-term debt growing?
Viracta Therapeutics Inc (VIRX) long-term debt fell by 100.0% year over year, from $24.9M to $0 in fiscal year 2023.
What was Viracta Therapeutics Inc's long-term debt in the most recent quarter?
Viracta Therapeutics Inc (VIRX) reported $16.9M in long-term debt in Q3 2024.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Viracta Therapeutics Inc (VIRX) reported on that line in every period on record.